Zepto was honored to participate in LSI USA 2025, joining the innovators, investors, and leaders shaping the future of healthcare. At LSI, we presented our proprietary GMR biosensor platform that offers a rapid, culture-independent solution helping clinicians act decisively in time-sensitive, high-risk scenarios. Our technology addresses critical gaps in early diagnosis and management by enabling detection of fungal cell-free DNA directly from plasma.
With strong clinical traction and a mission-driven team, Zepto is energized by the momentum coming out of LSI USA and looks forward to continued collaboration and growth. Thank you to the LSI team and the broader medtech community for the opportunity to share our work and connect with those driving the next wave of healthcare innovation.
About Zepto Life Technology
Zepto Life Technology is a molecular diagnostics company developing targeted liquid biopsy diagnostics for infectious diseases using proprietary Giant Magnetoresistance (GMR) biosensor technology. The company’s Zepto MDx platform is designed to enable highly sensitive detection and identification of pathogens directly from blood, beginning with invasive fungal infections.